 |
|
Narrowband UV-B Phototherapy vs Photochemotherapy in the Treatment of Chronic Plaque-Type Psoriasis
A Paired Comparison Study
Adrian Tanew, MD;
Sonja Radakovic-Fijan, MD;
Michael Schemper, PhD;
Herbert Hönigsmann, MD
Arch Dermatol. 1999;135:519-524.
Objective To compare the therapeutic efficacy of narrowband (TL-01) UV-B phototherapy vs photochemotherapy (psoralen–UV-A [PUVA]) in patients with chronic plaque-type psoriasis.
Design Open, nonrandomized, intraindividually controlled paired comparison study.
Setting Phototherapeutic unit in a university hospital.
Patients Twenty-five patients with chronic plaque-type psoriasis.
Interventions Paired irradiations with threshold erythemogenic doses of narrowband UV-B and PUVA were given to the patients' dorsal aspect including the arms and legs. Treatment was performed 3 times weekly until complete or almost complete clearing with one or both regimens or over a maximum period of 18 exposures.
Main Outcome Measures Assessment of the Psoriasis Area and Severity Index (PASI) in each half of the patient's dorsal aspect before and after treatment with the 2 regimens.
Results The median pretreatment PASI score of 16 (range, 6.2-23.4) was reduced by 84% to 2.5 (range, 0-12.6) by the narrowband UV-B treatment and by 89% to 1.8 (range, 0-8.2) by the PUVA treatment. Statistical analysis of these data showed a tendency for PUVA being superior to narrowband UV-B although the difference remained below the level of significance (P=.17). However, a clear effect of the pretreatment PASI score on the therapeutic outcome was found. Patients with higher baseline PASI scores responded significantly better to PUVA than to narrowband UV-B (P=.03).
Conclusions Our data demonstrate that in many patients with plaque-type psoriasis, narrowband UV-B is comparably as effective as PUVA and, given the lack of photosensitizer-related adverse reactions and the possibly lower long-term cancer risk, can be considered as first-line treatment. Treatment with PUVA, on the other hand, remains the mainstay for patients with high PASI scores who do not respond or whose psoriasis cannot be controlled adequately by narrowband UV-B.
From the Divison of Special and Environmental Dermatology, Department of Dermatology (Drs Tanew, Radakovic-Fijan, and Hönigsmann), Section of Clinical Biometrics, Department of Medical Computer Sciences (Dr Schemper), University of Vienna Medical School, Vienna, Austria.
RELATED ARTICLES
The Use of Narrowband UV-B (Tube Lamp) in the Management of Skin Disease
James Ferguson
Arch Dermatol. 1999;135(5):589-590.
EXTRACT
| FULL TEXT
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1999;135(5):617-618.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Randomized Double-blind Trial of the Treatment of Chronic Plaque Psoriasis: Efficacy of Psoralen-UV-A Therapy vs Narrowband UV-B Therapy.
Yones et al.
Arch Dermatol 2006;142:836-842.
ABSTRACT
| FULL TEXT
Low-Dose Excimer 308-nm Laser for the Treatment of Oral Lichen Planus
Arch Dermatol 2004;140:415-420.
Narrowband UV-B (TL-01) Phototherapy vs Oral 8-Methoxypsoralen Psoralen-UV-A for the Treatment of Chronic Plaque Psoriasis
Markham et al.
Arch Dermatol 2003;139:325-328.
ABSTRACT
| FULL TEXT
Recent advances: Dermatology
Foley
BMJ 2000;320:850-853.
FULL TEXT
Narrowband UV-B TL-01 vs. PUVA for Treating Psoriasis
Journal Watch Dermatology 1999;1999:2-2.
FULL TEXT
The Use of Narrowband UV-B (Tube Lamp) in the Management of Skin Disease
Ferguson
Arch Dermatol 1999;135:589-590.
FULL TEXT
|
